Patents by Inventor Ian Egle

Ian Egle has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 8377940
    Abstract: Compounds of Formula (I) wherein R1 and Q are as described in the specification, pharmaceutically-acceptable salts, methods of making, pharmaceutical compositions containing and methods for using the same.
    Type: Grant
    Filed: June 5, 2008
    Date of Patent: February 19, 2013
    Assignee: AstraZeneca AB
    Inventors: Joshua Clayton, Ian Egle, James Empfield, James Folmer, Methvin Isaac, Fupeng Ma, Abdelmalik Slassi
  • Patent number: 8377939
    Abstract: Compounds of Formula I: wherein R1 and Q are as described in the specification, pharmaceutically-acceptable salts, methods of making, pharmaceutical compositions containing and methods for using the same.
    Type: Grant
    Filed: June 6, 2008
    Date of Patent: February 19, 2013
    Assignee: AstraZeneca AB
    Inventors: Joshua Clayton, Ian Egle, James Empfield, James Folmer, Methvin Isaac, Fupeng Ma, Abdelmalik Slassi
  • Patent number: 8153638
    Abstract: Compounds of formula I: wherein R1, R2, R3, R4, R5, R6, R7, R8, R9 and n are as defined in the description, processes for the preparing the compounds, new intermediates employed in the preparation, pharmaceutical compositions containing the compounds, and uses of the compounds in therapy.
    Type: Grant
    Filed: August 23, 2010
    Date of Patent: April 10, 2012
    Assignee: AstraZeneca AB
    Inventors: Bradford Van Wagenen, Radhakrishnan Ukkiramapandian, Joshua Clayton, Ian Egle, James R. Empfield, Methvin Isaac, Fupeng Ma, Abdelmalik Slassi, Gary Steelman, Rebecca Urbanek, Sally Walsh
  • Publication number: 20110166155
    Abstract: The present invention is directed to compounds of formula I: wherein R1, R2, R3, R4, R5, R6, R7, R8, R9 and n are as defined for formula I in the description. The invention also relates to processes for the preparation of the compounds and to new intermediates employed in the preparation, pharmaceutical compositions containing the compounds, and to the use of the compounds in therapy.
    Type: Application
    Filed: January 6, 2011
    Publication date: July 7, 2011
    Inventors: Bradford VAN WAGENEN, Radhakrishnan UKKIRAMAPANDIAN, Joshua CLAYTON, Ian EGLE, James R. EMPFIELD, Methvin ISAAC, Fupeng MA, Abdelmalik SLASSI, Gary STEELMAN, Rebecca URBANEK, Sally WALSH
  • Patent number: 7968570
    Abstract: The present invention is directed to compounds of formula I: wherein R1, R2, R3, R4, R5, R6, R7, R8, R9 and n are as defined for formula I in the description. The invention also relates to processes for the preparation of the compounds and to new intermediates employed in the preparation, pharmaceutical compositions containing the compounds, and to the use of the compounds in therapy.
    Type: Grant
    Filed: August 12, 2005
    Date of Patent: June 28, 2011
    Assignee: AstraZeneca AB
    Inventors: Joshua Clayton, Fupeng Ma, Bradford Van Wagenen, Radhakrishnan Ukkiramapandian, Ian Egle, James Empfield, Methvin Isaac, Abdelmalik Slassi, Gary Steelman, Rebecca Urbanek, Sally Walsh
  • Publication number: 20110053953
    Abstract: Compounds of formula I: wherein R1, R2, R3, R4, R5, R6, R7, R8 and n are defined in the specification, methods for using said compounds, methods for making said compounds and pharmaceutical compositions containing said compounds.
    Type: Application
    Filed: January 31, 2008
    Publication date: March 3, 2011
    Inventors: Abdelmalik Slassi, Methvin Isaac, Joshua Clayton, Ian Egle, Babu Joseph, Fupeng Ma
  • Patent number: 7868008
    Abstract: The present invention is directed to compounds of formula I: wherein R1, R2, R3, R4, R5, R6, R7, R8, R9 and n are as defined for formula I in the description. The invention also relates to processes for the preparation of the compounds and to new intermediates employed in the preparation, pharmaceutical compositions containing the compounds, and to the use of the compounds in therapy.
    Type: Grant
    Filed: February 15, 2006
    Date of Patent: January 11, 2011
    Assignee: AstraZeneca AB
    Inventors: Bradford Van Wagenen, Radhakrishnan Ukkiramapandian, Joshua Clayton, Ian Egle, James Empfield, Methvin Isaac, Fupeng Ma, Abdelmalik Slassi, Gary Steelman, Rebecca Urbanek, Sally Walsh
  • Publication number: 20100317674
    Abstract: Compounds of formula I: wherein R1, R2, R3, R4, R5, R6, R7, R8, R9 and n are as defined in the description, processes for the preparing the compounds, new intermediates employed in the preparation, pharmaceutical compositions containing the compounds, and uses of the compounds in therapy.
    Type: Application
    Filed: August 23, 2010
    Publication date: December 16, 2010
    Inventors: Bradford Van Wagenen, Radhakrishnan Ukkiramapandian, Joshua Clayton, Ian Egle, James R. Empfield, Methvin Isaac, Fupeng Ma, Abdelmalik Slassi, Gary Steelman, Rebecca Urbanek, Sally Walsh
  • Publication number: 20100280082
    Abstract: Compounds of Formula (I) wherein R1, R2, R3 R4 and Q are as described in the specification, pharmaceutically-acceptable salts, methods of making, pharmaceutical compositions containing and methods for using the same.
    Type: Application
    Filed: June 5, 2008
    Publication date: November 4, 2010
    Applicant: AstraZeneca AB
    Inventors: Joshua Clayton, Ian Egle, James Empfield, James Folmer, Methvin Isaac, Fupeng Ma, Abdelmalik Slassi
  • Publication number: 20100267740
    Abstract: Compounds of Formula (I) wherein R1 and Q are as described in the specification, pharmaceutically-acceptable salts, methods of making, pharmaceutical compositions containing and methods for using the same.
    Type: Application
    Filed: June 5, 2008
    Publication date: October 21, 2010
    Applicant: AstraZeneca AB
    Inventors: Joshua Clayton, Ian Egle, James Empfield, James Folmer, Methvin Isaac, Fupeng Ma, Abdelmalik Slassi
  • Patent number: 7816354
    Abstract: The present invention is directed to compounds of Formula I: Wherein R1, R2, Y, m and n are further defined in the description. The invention also relates to processes for the preparation of the compounds and to new intermediates employed in the preparation, pharmaceutical compositions containing the compounds, and to the use of the compounds in therapy.
    Type: Grant
    Filed: December 6, 2006
    Date of Patent: October 19, 2010
    Assignee: AstraZeneca AB
    Inventors: Abdelmalik Slassi, Methvin Isaac, Ian Egle, Fupeng Ma, Babu Joseph, Joshua Clayton, Krzysztof Swierczek
  • Patent number: 7807706
    Abstract: Compounds of formula I: wherein R1, R2, R3, R4, R5, R6, R7, R8, R9 and n are as defined in the description, processes for the preparing the compounds, new intermediates employed in the preparation, pharmaceutical compositions containing the compounds, and uses of the compounds in therapy.
    Type: Grant
    Filed: February 15, 2006
    Date of Patent: October 5, 2010
    Assignee: AstraZeneca AB
    Inventors: Bradford Van Wagenen, Radhakrishnan Ukkiramapandian, Joshua Clayton, Ian Egle, James R. Empfield, Methvin Isaac, Fupeng Ma, Abdelmalik Slassi, Gary Steelman, Rebecca Urbanek, Sally Walsh
  • Patent number: 7799792
    Abstract: Compounds of Formula I: wherein R1, R2, R3, R4 and Q are as described in the specification, pharmaceutically-acceptable salts, methods of making, pharmaceutical compositions containing and methods for using the same.
    Type: Grant
    Filed: June 6, 2008
    Date of Patent: September 21, 2010
    Assignee: AstraZeneca AB
    Inventors: Joshua Clayton, Ian Egle, James Empfield, James Folmer, Methvin Isaac, Fupeng Ma, Abdelmalik Slassi
  • Patent number: 7790717
    Abstract: Compounds in accord with Formula I: wherein R1, L, A, B, D, E, m, n, x and y are as defined in the description, processes for the preparation of such compounds and to new intermediates employed in the preparation thereof, pharmaceutical compositions containing such compounds, and the use of such compounds in therapy and for the treatment of diseases mentioned in the specification.
    Type: Grant
    Filed: January 13, 2009
    Date of Patent: September 7, 2010
    Assignee: AstraZeneca AB
    Inventors: Ian Egle, Babu Joseph, Abdelmalik Slassi, Methvin Isaac, Fupeng Ma, Joshua Clayton
  • Publication number: 20090275578
    Abstract: The present invention is directed to compounds of formula I: wherein R1, R2, R3, R4, R5, R6, R7, R8, R9 and n are as defined for formula I in the description. The invention also relates to processes for the preparation of the compounds and to new intermediates employed in the preparation, pharmaceutical compositions containing the compounds, and to the use of the compounds in therapy.
    Type: Application
    Filed: August 12, 2005
    Publication date: November 5, 2009
    Applicants: AstraZeneca AB, NPS PHARMACEUTICALS, INC
    Inventors: Joshua Clayton, Fupeng Ma, Bradford Van Wagenen, Radhakrishnan Ukkiramapandian, Ian Egle, James Empfield, Methvin Isaac, Abdelmalik Slassi, Gary Steelman, Rebecca Urbanek, Sally Walsh
  • Publication number: 20090192169
    Abstract: Compounds of Formula I: wherein A, B, D, L, R1, R2, R3, R4, m, and n are as defined for Formula I in the description. The invention also relates to processes for the preparation of the compounds and to new intermediates employed in the preparation, pharmaceutical compositions containing the compounds, and to the use of the compounds in therapy.
    Type: Application
    Filed: March 29, 2007
    Publication date: July 30, 2009
    Inventors: Ian Egle, Methvin Isaac, Rebecca Urbanek, Frances M. McLaren, Sally B. Walsh, Gary B. Steelman, Dean G. Brown, David Nugiel, Deborah W. Chen, Abdelmalik Slassi, Fupeng Ma
  • Publication number: 20090149505
    Abstract: Compounds of Formula I: wherein R1, R2, R3, R4, R5, R6 and R7 are as defined in the description, processes for the preparing such compounds, new intermediates employed in their preparation, pharmaceutical compositions containing the compounds, and uses of the compounds in therapy.
    Type: Application
    Filed: February 6, 2007
    Publication date: June 11, 2009
    Applicant: AstraZeneca AB
    Inventors: James R. Empfield, James J. Folmer, James R. Arnold, Joshua Clayton, Abdelmalik Slassi, Methvin Isaac, Ian Egle, Fupeng Ma
  • Publication number: 20090124578
    Abstract: Compounds in accord with Formula I: wherein R1, L, A, B, D, E, m, n, x and y are as defined in the description, processes for the preparation of such compounds and to new intermediates employed in the preparation thereof, pharmaceutical compositions containing such compounds, and the use of such compounds in therapy and for the treatment of diseases mentioned in the specification.
    Type: Application
    Filed: January 13, 2009
    Publication date: May 14, 2009
    Applicant: ASTRAZENECA AB
    Inventors: Ian EGLE, Babu Joseph, Abdelmalik Slassi, Methvin Isaac, Fupeng Ma, Joshua Clayton
  • Publication number: 20090111830
    Abstract: The present invention is directed to compounds of formula I: wherein R1, R2, R3, R4, R5, R6, R7, R8, R9 and n are as defined for formula I in the description. The invention also relates to processes for the preparation of the compounds and to new intermediates employed in the preparation, pharmaceutical compositions containing the compounds, and to the use of the compounds in therapy.
    Type: Application
    Filed: February 15, 2006
    Publication date: April 30, 2009
    Applicant: AstraZeneca AB
    Inventors: Bradford Van Wagenen, Radhakrishnan Ukkiramapandian, Joshua Clayton, Ian Egle, James R. Empfield, Methvin Isaac, Fupeng Ma, Abdelmalik Slassi, Gary Steelman, Rebecca Urbanek, Sally Walsh
  • Publication number: 20090069340
    Abstract: Compounds of Formula (I), wherein R1, R2, R3, R4, R5, R6, X, and n are as defined for Formula (I) in the description, processes for the preparation of the compounds and new intermediates employed in the preparation, pharmaceutical compositions containing the compounds, and the use of the compounds in the treatment or prevention of neurological and psychiatric disorders associated with glutamate dysfunction.
    Type: Application
    Filed: December 22, 2005
    Publication date: March 12, 2009
    Applicant: AstraZeneca AB
    Inventors: Michael Balestra, Heather Bunting, Deborah Chen, Ian Egle, Janet Forst, Jennifer Frey, Methvin Isaac, Fupeng Ma, David Nugiel, Abdelmalik Slassi, Gary Steelman, Guang-Ri Sun, Babu Sundar, Radhakrishnan Ukkiramapandian, Rebecca Urbanek, Sally Walsh